New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 27, 2014
09:28 EDTHSH, JKS, FRO, ARO, SDRL, BCRX, PFE, AZN, PF, PPC, SPLSOn The Fly: Pre-market Movers
HIGHER: Pilgrim's Pride (PPC), up 5% after proposing to acquire Hillshire Brands (HSH) for $45.00 per share cash. Hillshire up 21% following the news, while Pinnacle Foods (PF), which has agreed to be acquired by Hillshire, is down 6.4%... BioCryst (BCRX), up 19% after announcing "positive" results from OPuS-1, a trial of BCX4161... Seadrill (SDRL), up 2.6% after signing investment and cooperation pact with Rosneft and North Atlantic... Aeropostale (ARO), up 11% after $150M financing transaction with Sycamore. LOWER: AstraZeneca (AZN), down 1.7% after downgraded at Societe Generale following Pfizer (PFE) confirming it won't bid for AstraZeneca after rejection of proposal. Pfizer shares are up 1% after the news... Staples (SPLS), down 1% after downgraded at Goldman... Frontline (FRO), down 7.4% after saying it sees weaker Q2 operational results... JinkoSolar (JKS), down 7.8% after reporting lower than expected Q1 earnings results.
News For HSH;PPC;PF;AZN;PFE;BCRX;SDRL;ARO;FRO;JKS;SPLS From The Last 14 Days
Check below for free stories on HSH;PPC;PF;AZN;PFE;BCRX;SDRL;ARO;FRO;JKS;SPLS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
August 18, 2014
07:03 EDTJKSJinkoSolar sees FY14 total soluar module shipments in range of 2.9-3.2GW
This total includes 2.3GW to 2.5GW module shipments to third parties, and 600 MW to 650 MW for its own downstream projects. Full year project development scale is expected to be above 600 MW.
07:03 EDTJKSJinkoSolar sees Q3 total solar module shipments of 800-850MW
Subscribe for More Information
07:02 EDTJKSJinkoSolar reports Q2 total solar product shipments amounted to 695.5 MW
That total consists of 570.8 MW of solar modules, 54.1 MW of silicon wafers and 34.6 MW of solar cells. As of June 30, 2014, the Company has connected 252 MW of solar projects to the grid and expects to connect another 100 MW of solar projects during the third quarter.
07:02 EDTJKSJinkoSolar reports Q2 non-GAAP EPS 80c, consensus 76c
Subscribe for More Information
06:09 EDTAROAeropostale volatility elevated into Q2 and new leadership outlook
Aeropostale September call option implied volatility is at 93, October is at 75, January is at 85; compared to its 26-week average of 58 according to Track Data, suggesting large near term price movement into the expected release of Q2 results on August 21.
August 15, 2014
07:44 EDTJKSJinkoSolar volatility low into Q2 and outlook
Subscribe for More Information
August 14, 2014
17:16 EDTHSHPaulson & Co gives quarterly update on stakes
Subscribe for More Information
17:05 EDTPFEPfizer says FDA accepted for review BLA for bivalent recombinant LP2086
Pfizer announced that the FDA has accepted for review the Biologics License Application,BLA, for bivalent recombinant LP2086, the company’s vaccine candidate for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in 10 through 25 year olds. The FDA has also granted Priority Review designation for the BLA, providing an anticipated Prescription Drug User Fee Act, PDUFA, action date of February 14, 2015. “Pfizer has closely collaborated with the FDA since 2008 to develop our meningococcal B vaccine candidate with the intent to help prevent this devastating disease,” said Dr. Emilio Emini, senior vice president of Vaccine Research and Development for Pfizer. “Both the acceptance of Pfizer’s Biologics License Application today, and its Priority Review designation, are significant regulatory milestones that underscore the importance of our efforts to expedite the approval and subsequent availability of our meningococcal B vaccine for U.S. adolescents.”
12:01 EDTAZNThird Point gives quarterly update on stakes
NEW STAKES: Rackspace (RAX), Finisar (FNSR), Amgen (AMGN), Ally Financial (ALLY), and AstraZeneca (AZN). INCREASED STAKES: Dollar General (DG) and Dow Chemical (DOW). DECREASED STAKES: FedEx (FDX), Hertz (HTZ), T-Mobile (TMUS) and Intrexon (XON). LIQUIDATED STAKES: Google Class A (GOOGL), Verizon (VZ) and Mondelez (MDLZ).
August 13, 2014
12:16 EDTJKSCanadian Solar soars after results top estimates
Subscribe for More Information
10:03 EDTHSH, PFPinnacle Foods says Hillshire Brands failed deal caused 'six weeks' distraction
Pinnacle Foods (PF) says it has not lost any key executives following the "six weeks of distraction" caused by its aborted merger with Hillshire Brand (HSH). The company said it lost six weeks to investigate other M&A during that time, but that Pinnacle plans to be a consolidator and is back and active on exploring M&A opportunities. Comments from Pinnacle Foods' Q2 earnings conference call.
09:15 EDTJKSOn The Fly: Pre-market Movers
Subscribe for More Information
08:34 EDTPFPinnacle Foods backs FY14 EPS $1.70-$1.75, consensus $1.74
Subscribe for More Information
08:33 EDTPFPinnacle Foods reports Q2 North American Retail sales up 11% to $536.2M
Subscribe for More Information
08:32 EDTPFPinnacle Foods reports Q2 EPS 33c, consensus 33c
Reports Q2 revenue $617.8M, consensus $629.33M
08:31 EDTAZNAstraZeneca says Phase 3 trials of lesinurad for gout met primary endpoints
AstraZeneca announced top-line results from CLEAR1, CLEAR2 and CRYSTAL, the pivotal Phase III clinical trials investigating the potential of lesinurad, a selective uric acid re-absorption inhibitor, as a combination therapy for the treatment of patients with symptomatic gout. Lesinurad is an investigational agent that inhibits the URAT1 transporter, increasing uric acid excretion and thereby lowering serum uric acid. In the CLEAR1 and CLEAR2 trials, both lesinurad 200mg and 400mg in combination with allopurinol met the primary endpoint, with a statistically significant higher proportion of patients reaching the target sUA goal of <6.0mg/dL at month 6 compared to allopurinol alone. In the CRYSTAL trial, lesinurad 400mg in combination with febuxostat met the primary endpoint, with a statistically significant higher proportion of patients reaching the target sUA goal of <5.0mg/dL at month 6 compared to febuxostat alone. Although lesinurad 200mg did not achieve statistical significance at month 6, this dose in combination with febuxostat, was superior to placebo plus febuxostat at all other time points. Results from these Phase III clinical trials will be submitted to a scientific meeting later in 2014. The company is proceeding with preparation of regulatory submissions for lesinurad 200mg combination therapy.
07:32 EDTHSHHillshire Brands not providing public targets for FY15
Subscribe for More Information
07:31 EDTHSHHillshire Brands reports Q4 adjusted EPS 33c, consensus 26c
Reports Q4 revenue $1.1B, consensus $994.1M. As previously announced, on July 1, Hillshire Brands entered into a definitive agreement with Tyson Foods (TSN) under which Tyson will acquire all outstanding shares of Hillshire Brands for $63 per share. On August 12, 2014, each of Tyson and Hillshire Brands received a request for additional information, each often referred to as a “second request,” from the Antitrust Division of the Department of Justice in connection with the proposed acquisition. Each second request was issued pursuant to the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. The second requests relate only to a very small portion of the combined Tyson/Hillshire Brands business, and the parties are working expeditiously to resolve this matter with the Antitrust Division. Tyson and Hillshire Brands continue to expect that the transaction, which remains subject to customary closing conditions, will be completed by September 27.
07:21 EDTBCRXBioCryst receives additional NIAID funding for BCX4430
Subscribe for More Information
06:32 EDTJKSJinkoSolar signs five-year development agreement with Lishui City
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use